Slides – 2022 comparative results under IFRS 17 and IFRS 9
2022 Comparative Results under IFRS 17 and IFRS 9
1
Caution regarding forward-looking statements
From time to time, Manulife makes written and/or oral forward-looking statements, including in this presentation. In addition, our representatives may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the "safe harbour" provisions of Canadian provincial securities laws and the
The forward-looking statements in this presentation include, but are not limited to, statements with respect to the expected improved stability of Manulife's earnings, book value and capital under IFRS 17 and IFRS 9; the variance between net income attributed to shareholders and core earnings as our investment activities further align to IFRS 17 and hedge accounting programs mature; the Company's strategic priorities and 2025 targets for its highest potential businesses, core earnings contribution from
Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to the performance, volatility and correlation of equity markets, interest rates, credit and swap spreads, currency rates, investment losses and defaults, market liquidity and creditworthiness of guarantors, reinsurers and counterparties); the ongoing prevalence of COVID-19, including any variants, as well as actions that have been, or may be taken by governmental authorities in response to COVID-19, including the impact of any variants; changes in laws and regulations; changes in accounting standards applicable in any of the territories in which we operate; changes in regulatory capital requirements applicable in any of the territories in which we operate; our ability to execute strategic plans and changes to strategic plans; downgrades in our financial strength or credit ratings; our ability to maintain our reputation; impairments of goodwill or intangible assets or the establishment of provisions against future tax assets; the accuracy of estimates relating to morbidity, mortality and policyholder behaviour; the accuracy of other estimates used in applying accounting policies, actuarial methods and embedded value methods; our ability to implement effective hedging strategies and unforeseen
consequences arising from such strategies; our ability to source appropriate assets to back our long-dated liabilities; level of competition and consolidation; our ability to market and distribute products through current and future distribution channels; unforeseen liabilities or asset impairments arising from acquisitions and dispositions of businesses; the realization of losses arising from the sale of investments classified as fair value through other comprehensive income; our liquidity, including the availability of financing to satisfy existing financial liabilities on expected maturity dates when required; obligations to pledge additional collateral; the availability of letters of credit to provide capital management flexibility; accuracy of information received from counterparties and the ability of counterparties to meet their obligations; the availability, affordability and adequacy of reinsurance; legal and regulatory proceedings, including tax audits, tax litigation or similar proceedings; our ability to adapt products and services to the changing market; our ability to attract and retain key executives, employees and agents; the appropriate use and interpretation of complex models or deficiencies in models used; political, legal, operational and other risks associated with our non-North American operations; acquisitions or divestitures, and our ability to complete transactions; environmental concerns; our ability to protect our intellectual property and exposure to claims of infringement; and our inability to withdraw cash from subsidiaries.
Additional information about material risk factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Management's Discussion and Analysis ("MD&A") in our most recent interim report under "Risk Management and Risk Factors Update" and "Critical Actuarial and Accounting Policies", under "Risk Management and Risk Factors" and "Critical Actuarial and Accounting Policies" in the MD&A in our most recent annual report and, in the "Risk Management" note to the consolidated financial statements in our most recent annual and interim reports and elsewhere in our filings with Canadian and
2
Note to readers
- Our 2022 results have been restated for the adoption of IFRS 17 "Insurance Contracts", including the other comprehensive income option, and IFRS 9 "Financial Instruments"
- The restated 2022 results may not be fully representative of our market risk profile, as the transition of our general fund portfolio for asset- liability matching purposes under IFRS 17 and IFRS 9 was not completed until early 2023. Consequently, year-over-year variations between our 2023 results compared to the 2022 results should be viewed in this context
- In addition, our 2022 results are also not directly comparable to 2023 results because IFRS 9 hedge accounting and expected credit loss (ECL) principles are applied prospectively effective
January 1, 2023 . Accordingly, we have also presented comparative quarterly 2022 results in our first quarter of 2023 MD&A as if IFRS had allowed such principles to be implemented for 2022 as "transitional" 2022 results - IFRS 9 hedge accounting - Manulife uses derivatives for economic hedging purposes. Effective
January 1, 2023 , the Company designated additional existing derivatives in new hedge accounting relationships, with the objective to reduce accounting mismatches between reporting of the change in the value of hedging derivatives in net income and the reporting of the change in financial risk of insurance contract liabilities reported in other comprehensive income (OCI)without hedge accounting and net income with hedge accounting - Our restated 2022 core earnings and transitional net income are non-GAAP financial measures and will also reflect the impact of the IFRS 9 principles noted above (e.g., hedge accounting and ECL) as well as the expected long-term (ELT) returns for the corresponding period. Note that the core investment gains recognized under the previous accounting regime are no longer applicable under the restated 2022 core earnings
3
Agenda
2022 financial highlights under IFRS 17
Understanding 2022 comparative results
Appendix
4
2022 financial highlights
under IFRS 17
President & Chief Executive Officer
5
Attachments
Disclaimer
slides 2023 q1
Slides – Conceptual overview of Manulife's adoption of IFRS 17 and IFRS 9
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News